Claims
- 1. A purified polypeptide comprising an amino acid sequence selected from the groups consisting of: SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.
- 2. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO: 9.
- 3. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO: 10.
- 4. The polypeptide of claim 1, wherein said polypeptide consists of an MCH-2R dog, ferret, or rhesus sequence comprising SEQ ID NO: 11.
- 5. The polypeptide of claim 1, wherein said polypeptide comprises a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.
- 6. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO: 1.
- 7. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO: 2.
- 8. The polypeptide of claim 5, wherein said polypeptide consists of SEQ ID NO: 3.
- 9. A purified nucleic acid comprising a nucleotide sequence encoding the polypeptide of any one of claims 1-8.
- 10. A purified nucleic acid comprising a nucleotide sequence selected from the group consisting of: SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, the complement of SEQ ID NO: 12, the complement of SEQ ID NO: 13, the complement of SEQ ID NO: 14, and the complement of SEQ ID NO: 15.
- 11. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 12 or the complement thereof.
- 12. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 13 or the complement thereof.
- 13. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 14 or the complement thereof.
- 14. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 15 or the complement thereof.
- 15. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 5 or the complement thereof.
- 16. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 6 or the complement thereof.
- 17. The purified nucleic acid of claim 10, wherein said nucleotide sequence comprises SEQ ID NO: 7 or the complement thereof.
- 18. A recombinant nucleic acid comprising either (a) a nucleotide sequence encoding the amino acid sequence of any one of claims 1-8 or (b) the sequence of any one of claims 10-17.
- 19. The recombinant nucleic acid of claim 18, wherein said recombinant nucleic acid is an expression vector.
- 20. A recombinant cell comprising an expression vector encoding the amino acid sequence of any one of claim 1-8 functionally coupled to a promoter recognized by said cell.
- 21. A recombinant cell made by a process comprising the step of introducing into said cell the expression vector of claim 19.
- 22. A method of measuring the ability of a compound to affect MCH-2R activity comprising the steps of:
a) contacting a recombinant cell with said compound, wherein said recombinant cell comprises a recombinant nucleic acid expressing a functional MCH-2R that comprises the amino acid sequence of any one of claim 1-8; and b) measuring MCH-2R activity.
- 23. The method of claim 22, wherein said method further comprises the use of an MCH-2R agonist.
- 24. A method of preparing a MCH-2R polypeptide comprising the step of growing the recombinant cell of claim 20 under conditions wherein said polypeptide is expressed from said expression vector.
- 25. A method of evaluating the ability of an MCH-2R active compound to exert an in vivo effect comprising the steps of:
a) measuring the ability of said compound to affect MCH-2R activity; b) administering said compound to a subject selected from the group consisting of: a rhesus monkey, a dog, and a ferret; and c) measuring the effect of said compound on said subject.
- 26. The method of claim 25, wherein said step (c) measures alterations in weight.
- 27. The method of claim 25, wherein said step (c) measures energy metabolism.
- 28. The method of claim 25, wherein said step (c) measures appetite.
- 29. The method of claim 25, wherein said step (c) measures sexual activity.
- 30. The method of any one of claim 25-29, wherein said subject is said rhesus monkey.
- 31. The method of any one of claims 25-29, wherein said subject is said dog.
- 32. The method of any one of claims 25-29, wherein said subject is said ferret.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims priority to provisional application U.S. Serial No. 60/294,747, filed May 31, 2001, hereby incorporated by reference herein.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/US02/16702 |
5/28/2002 |
WO |
|